Professor Matthew Hurles discusses the Deciphering Developmental Disorders study
Professor Matthew Hurles, project lead for DDD study and Congenica founder, discsuses his projects, advancements in data analysis and interpretation
Congenica announces Early Access Program for its novel Precision Oncology Solution
Congenica launches early access program for its new CE-IVD Precision Oncology Solution
Congenica approved as supplier on Government G-Cloud 13 framework
Congenica is an approved supplier on UK Government G-Cloud 13 framework
Congenica awarded European contract to develop NGS analysis workflow in oncology
Congenica awarded a contract to develop standardised NGS workflows in oncology for a group of 7 Central European hospitals by the Medical University Graz
The Real Costs of Rare Disease
Congenica welcomed an expert panel to discuss the true cost of rare disease, from birth to diagnosis, childhood to adulthood.
Congenica and FDB collaborate to incorporate PGx into Clinical Decision Support Systems
Congenica and FDB announce a collaboration agreement to develop the delivery of pharmacogenomics (PGx) results into point of care prescribing.
Genomics in South Africa
A personal view of Genomics in South Africa by Diane May, mother to Matthew who has been diagnosed with Morquio syndrome.
Congenica gives employees ‘cost of living’ bonus
Congenica employees receive one off bonus to help with increases in cost of living
Pharmacogenomics: Personalised psychotropic prescribing in adults with intellectual disabilities
Pharmacogenomics: An opportunity for personalised psychotropic prescribing in adults with intellectual disabilities
Congenica announces partnership with Avesthagen
Congenica announces a partnership with Avesthagen, strengthenening Congenica’s presence in India
Living with a rare disease in India
As part of our series looking at rare diseases around the world, guest blogger Swapna Roopesh discusses living with a rare disease in India.
Collaborative development of novel Precision Oncology Solution
Congenica has selected the GenomOncology Precision Oncology Platform for the development of a novel ground-breaking CE-IVD Precision Oncology Solution.